ATE455113T1 - 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors - Google Patents
3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptorsInfo
- Publication number
- ATE455113T1 ATE455113T1 AT06724410T AT06724410T ATE455113T1 AT E455113 T1 ATE455113 T1 AT E455113T1 AT 06724410 T AT06724410 T AT 06724410T AT 06724410 T AT06724410 T AT 06724410T AT E455113 T1 ATE455113 T1 AT E455113T1
- Authority
- AT
- Austria
- Prior art keywords
- 4alkyl
- group
- haloc1
- 4alkoxy
- dopamine
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0507601.3A GB0507601D0 (en) | 2005-04-14 | 2005-04-14 | Compounds |
| PCT/EP2006/003553 WO2006108700A1 (en) | 2005-04-14 | 2006-04-12 | 3-triazolylthioalkyl-3-azabicyclo (3 - 1 - o) hexanes and their use as dopamine d3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE455113T1 true ATE455113T1 (de) | 2010-01-15 |
Family
ID=34611146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06724410T ATE455113T1 (de) | 2005-04-14 | 2006-04-12 | 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7803820B2 (de) |
| EP (1) | EP1869018B1 (de) |
| JP (1) | JP5150480B2 (de) |
| AT (1) | ATE455113T1 (de) |
| DE (1) | DE602006011725D1 (de) |
| ES (1) | ES2339274T3 (de) |
| GB (1) | GB0507601D0 (de) |
| WO (1) | WO2006108700A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE451364T1 (de) * | 2004-02-23 | 2009-12-15 | Glaxo Group Ltd | Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| JP5068747B2 (ja) * | 2005-06-14 | 2012-11-07 | グラクソ グループ リミテッド | ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体 |
| ATE487715T1 (de) * | 2005-08-22 | 2010-11-15 | Glaxo Group Ltd | Triazolderivate als modulatoren von dopamin-d3- rezeptoren |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| ATE498619T1 (de) * | 2006-04-03 | 2011-03-15 | Glaxo Group Ltd | Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren |
| US8222266B2 (en) * | 2006-04-03 | 2012-07-17 | Glaxo Group Limited | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
| RU2012102094A (ru) | 2009-06-26 | 2013-08-10 | Панацеа Биотек Лтд. | Новые азабициклогексаны |
| US9108910B2 (en) | 2011-02-15 | 2015-08-18 | Ube Industries, Ltd. | Industrial methods for producing arylsulfur pentafluorides |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035369A1 (es) * | 2000-11-14 | 2004-05-12 | Smithkline Beecham Plc | Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| ATE451364T1 (de) * | 2004-02-23 | 2009-12-15 | Glaxo Group Ltd | Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| JP5068747B2 (ja) * | 2005-06-14 | 2012-11-07 | グラクソ グループ リミテッド | ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体 |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| ATE487715T1 (de) * | 2005-08-22 | 2010-11-15 | Glaxo Group Ltd | Triazolderivate als modulatoren von dopamin-d3- rezeptoren |
| GB0517193D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| GB0616574D0 (en) | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-04-14 GB GBGB0507601.3A patent/GB0507601D0/en not_active Ceased
-
2006
- 2006-04-12 EP EP06724410A patent/EP1869018B1/de not_active Expired - Lifetime
- 2006-04-12 DE DE602006011725T patent/DE602006011725D1/de not_active Expired - Lifetime
- 2006-04-12 ES ES06724410T patent/ES2339274T3/es not_active Expired - Lifetime
- 2006-04-12 US US11/911,035 patent/US7803820B2/en not_active Expired - Fee Related
- 2006-04-12 WO PCT/EP2006/003553 patent/WO2006108700A1/en not_active Ceased
- 2006-04-12 AT AT06724410T patent/ATE455113T1/de not_active IP Right Cessation
- 2006-04-12 JP JP2008505839A patent/JP5150480B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008535885A (ja) | 2008-09-04 |
| GB0507601D0 (en) | 2005-05-18 |
| US20080176917A1 (en) | 2008-07-24 |
| DE602006011725D1 (de) | 2010-03-04 |
| WO2006108700A1 (en) | 2006-10-19 |
| EP1869018A1 (de) | 2007-12-26 |
| JP5150480B2 (ja) | 2013-02-20 |
| EP1869018B1 (de) | 2010-01-13 |
| ES2339274T3 (es) | 2010-05-18 |
| US7803820B2 (en) | 2010-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| DE602006011725D1 (de) | 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| EP2060570A3 (de) | Azalbicyclo[3.1.0]Hexaderivate und ihre Verwendung als Modulatoren des Dopamin-D3-Rezeptors | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
| IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| DE602006019221D1 (de) | Von dopamin-d3-rezeptoren | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| ATE534625T1 (de) | Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung | |
| UY29204A1 (es) | Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| ATE532780T1 (de) | Chinoline und ihre therapeutische verwendung | |
| ATE512142T1 (de) | Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |